Avenue Therapeutics IPO Presentation Deck
October 2022, 30 slides
  1. Avenue Therapeutics
  2. Related Decks
  3. IPO Presentation Decks
avenue | Avenue Therapeutics
avenue | Avenue Therapeutics
offering summary | Avenue Therapeutics
executive summary | Avenue Therapeutics
our clinical stage assets address large unmet patient and market needs in the therapeutic space | Avenue Therapeutics
our pipeline has near term value inflection points | Avenue Therapeutics
| Avenue Therapeutics
is being developed for epilepsy and acute anxiety | Avenue Therapeutics
is a selective receptor agonist that produces and activity receptor | Avenue Therapeutics
may have a more tolerable side effect profile compared to nonselective due to greater subtype selectively | Avenue Therapeutics
have significant unmet needs for therapies with improved safety profiles | Avenue Therapeutics
acute anxiety patients also utilize today and have significant unmet need for therapies with improved safety profiles | Avenue Therapeutics
can target the large market of patients prescribed by targeting drug resistant epilepsy orphan epilepsy or acute anxiety | Avenue Therapeutics
has a compelling profile to address this market | Avenue Therapeutics
preclinical in studies demonstrate efficacy in multiple epilepsy models | Avenue Therapeutics
preclinical in studies demonstrate efficacy in multiple anxiety models | Avenue Therapeutics
completed clinical studies and demonstrated safety across trials | Avenue Therapeutics
clinical studies demonstrate positive sedation and cognition effects | Avenue Therapeutics
we plan to initiate two phase studies that we expect to translate well into later development programs warning | Avenue Therapeutics
| Avenue Therapeutics
| Avenue Therapeutics
has a unique dual mechanism of action among analgesics | Avenue Therapeutics
safety and efficacy has been demonstrated in two phase trials in over patients | Avenue Therapeutics
regulatory history and now a path forward for | Avenue Therapeutics
| Avenue Therapeutics
we are searching the world for first rate rare disease assets with these characteristics | Avenue Therapeutics
avenue company overview | Avenue Therapeutics
we are led by an experienced management team and board of directors fortress | Avenue Therapeutics
exclusivity | Avenue Therapeutics
executive summary | Avenue Therapeutics
See More
Avenue Therapeutics
IPO Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Anxiety
Clinical development
Related decks
Bionomics
Investor Presentation
April 2022
MindMed
Investor Presentation
June 2023
Bionomics
IPO
December 2021
ATAI
Investor Presentation
October 2022
Hillstream BioPharma
Investor Presentation
July 2023
ATAI
Investor Conference
May 2023
AbCellera
Results
November 2022
Neumora Therapeutics
IPO
September 2023
Bionomics
Investor Presentation
April 2022
MindMed
Investor Presentation
June 2023
Bionomics
IPO
December 2021
ATAI
Investor Presentation
October 2022
Hillstream BioPharma
Investor Presentation
July 2023
ATAI
Investor Conference
May 2023
AbCellera
Results
November 2022
Neumora Therapeutics
IPO
September 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights